Greenleaf Trust Buys 1,291 Shares of Boston Scientific Co. (NYSE:BSX)

Greenleaf Trust lifted its stake in shares of Boston Scientific Co. (NYSE:BSX) by 5.1% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 26,593 shares of the medical equipment provider’s stock after purchasing an additional 1,291 shares during the period. Greenleaf Trust’s holdings in Boston Scientific were worth $2,375,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in BSX. Quarry LP bought a new stake in shares of Boston Scientific during the 2nd quarter worth approximately $33,000. Czech National Bank raised its stake in shares of Boston Scientific by 7.1% during the 3rd quarter. Czech National Bank now owns 299,989 shares of the medical equipment provider’s stock worth $25,139,000 after purchasing an additional 19,833 shares in the last quarter. GAMMA Investing LLC raised its stake in shares of Boston Scientific by 39.9% during the 3rd quarter. GAMMA Investing LLC now owns 17,432 shares of the medical equipment provider’s stock worth $1,461,000 after purchasing an additional 4,972 shares in the last quarter. Miracle Mile Advisors LLC raised its stake in shares of Boston Scientific by 4.0% during the 3rd quarter. Miracle Mile Advisors LLC now owns 5,252 shares of the medical equipment provider’s stock worth $440,000 after purchasing an additional 203 shares in the last quarter. Finally, Bank of New Hampshire increased its holdings in shares of Boston Scientific by 52.6% during the 3rd quarter. Bank of New Hampshire now owns 2,235 shares of the medical equipment provider’s stock worth $187,000 after acquiring an additional 770 shares during the last quarter. Institutional investors own 89.07% of the company’s stock.

Boston Scientific Stock Performance

NYSE:BSX opened at $102.40 on Monday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.02 and a current ratio of 1.48. Boston Scientific Co. has a fifty-two week low of $62.63 and a fifty-two week high of $104.25. The company has a market cap of $150.92 billion, a price-to-earnings ratio of 84.63, a PEG ratio of 2.69 and a beta of 0.80. The stock has a fifty day moving average price of $93.47 and a 200-day moving average price of $86.27.

Analyst Ratings Changes

BSX has been the topic of a number of recent analyst reports. Sanford C. Bernstein boosted their target price on Boston Scientific from $92.00 to $100.00 and gave the stock an “outperform” rating in a report on Thursday, October 24th. Needham & Company LLC reissued a “hold” rating on shares of Boston Scientific in a report on Wednesday, November 27th. StockNews.com raised Boston Scientific from a “hold” rating to a “buy” rating in a report on Wednesday, January 29th. TD Cowen boosted their target price on Boston Scientific from $100.00 to $110.00 and gave the stock a “buy” rating in a report on Thursday, December 12th. Finally, Royal Bank of Canada boosted their target price on Boston Scientific from $95.00 to $98.00 and gave the stock an “outperform” rating in a report on Thursday, October 24th. One equities research analyst has rated the stock with a hold rating, twenty-one have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Boston Scientific has a consensus rating of “Buy” and an average price target of $99.73.

Insider Buying and Selling

In related news, EVP John Bradley Sorenson sold 4,119 shares of the company’s stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $90.02, for a total transaction of $370,792.38. Following the completion of the sale, the executive vice president now directly owns 35,319 shares in the company, valued at $3,179,416.38. This represents a 10.44 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Edward J. Ludwig sold 4,877 shares of the company’s stock in a transaction on Thursday, November 21st. The stock was sold at an average price of $91.63, for a total value of $446,879.51. Following the sale, the director now owns 39,398 shares of the company’s stock, valued at approximately $3,610,038.74. This represents a 11.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 29,989 shares of company stock worth $2,702,261 in the last ninety days. 0.50% of the stock is owned by insiders.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.